Ma Tiantian, Gao Shuang, Zhang Beiru, Li Xinqiu, Dong Jie, Bai Yu
Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University, Beijing 100034, China.
Key Laboratory of Renal Disease, Ministry of Health, Beijing 100034, China.
Clin Kidney J. 2025 May 27;18(6):sfaf165. doi: 10.1093/ckj/sfaf165. eCollection 2025 Jun.
BACKGROUND: This study investigated the association between triglyceride/high-density lipoprotein cholesterol (TG/HDL-C), total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) and clinical outcomes in patients with peritoneal dialysis (PD) through the present prospective cohort study. METHODS: This study is an observational analysis based on PD Telemedicine-assisted Platform Cohort Study. The lipid data was defined as the average levels for the first 3 months after receiving PD, including TG, TG and HDL-C. The primary outcome was all-cause mortality, and the secondary outcomes were major adverse cardiovascular events (MACE), modified MACE+ and hemodialysis transfer. RESULTS: A total of 5875 PD patients were enrolled. By cubic spline regression analysis, the cut-off value of TG/HDL-C and TC/HDL-C were 1.25 and 4.20, respectively. During the follow-up time, 1098 (7.75/100 person-years) patients died, and the leading cause of mortality was cardiovascular diseases [686 (4.85/100 person-years)]. MACE and modified MACE+ occurred in 845 (6.09/100 person-years) and 1459 (10.83/100 person-years) patients, respectively. There were 719 patients (5.08/100 person-years) transferred to hemodialysis. The incidence of all-cause mortality, MACE and modified MACE+ were significant higher in groups with elevated TG/HDL-C and TC/HDL-C ( < .001). CONCLUSIONS: Among patients treated with PD, the elevated TG/HDL-C and TC/HDL-C were independently associated with increased risk of mortality and cardiovascular events.
背景:本前瞻性队列研究探讨了腹膜透析(PD)患者甘油三酯/高密度脂蛋白胆固醇(TG/HDL-C)、总胆固醇/高密度脂蛋白胆固醇(TC/HDL-C)与临床结局之间的关联。 方法:本研究是基于PD远程医疗辅助平台队列研究的观察性分析。脂质数据定义为开始PD治疗后前3个月的平均水平,包括TG、TC和HDL-C。主要结局为全因死亡率,次要结局为主要不良心血管事件(MACE)、改良MACE+和血液透析转换。 结果:共纳入5875例PD患者。通过三次样条回归分析,TG/HDL-C和TC/HDL-C的截断值分别为1.25和4.20。随访期间,1098例(7.75/100人年)患者死亡,主要死亡原因是心血管疾病[686例(4.85/100人年)]。MACE和改良MACE+分别发生在845例(6.09/100人年)和1459例(10.83/100人年)患者中。719例患者(5.08/100人年)转为血液透析。TG/HDL-C和TC/HDL-C升高组的全因死亡率、MACE和改良MACE+发生率显著更高(P<0.001)。 结论:在接受PD治疗的患者中,TG/HDL-C和TC/HDL-C升高与死亡风险和心血管事件增加独立相关。
Cochrane Database Syst Rev. 2025-5-6
Cochrane Database Syst Rev. 2022-8-8
Cochrane Database Syst Rev. 2022-2-24
J Atheroscler Thromb. 2023-11-1
Front Endocrinol (Lausanne). 2022
BMC Nephrol. 2022-10-24
Nat Rev Nephrol. 2022-12